Amisulpride as adjunct to clozapine in treatment-resistant schizophrenia and schizoaffective disorder: An open-label pilot study

South African Journal of Psychiatry

Volumn 12, Issue 1, 2006, Pages 17-20

  Koen, Liezl ^a   Niehaus, Dana J ^a   Schulte, Angelica ^a   Muller, Jaqueline ^a   Emsley, Robin ^a   Oosthulzen, Piet ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; LITHIUM CARBONATE; PHENYTOIN; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 33645988847     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rupp A, Keith SJ. The costs of schizophrenia. Psychiatr Clin North Am 1993; 16: 423.
2. Wirshing WC, Marder SR, Van Putten T, Ames D. Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1994.
3. Emsley RA. Partial response to antipsychotic treatment: The patient with enduring symptoms. J Clin Psychiatry 1999; 60: suppl. 23, 10-13.
4. Kane J, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
5. Emsley R. Outcome of first-episode schizophrenia and the new antipsychotics: A literature review. S Afr Med J 1996; 86: 729-734.
6. Breier A, Buchanan RW, Kirkpatrick B, et al. Effect of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-26.
7. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. European Psychiatry 2005; 20: 409-415.
8. Conley RR, Buchanan RW. Evaluation of treatment resistant schizophrenia. Schizophr Bull 1997; 23: 663-674.
9. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-573.
10. Moller HJ. Amisulipride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand Suppl 2000; 101: 17-22.
11. Moller HJ, Boyer P, Fleurot O, Rein W, and the PROD-ASLP study group. Improvement of acute exacerbations of schizophrenia with amisulpiride: a comparison with haloperidol. Psychopharmacology 1997; 132: 396-401.
12. Peuskens J, Bech P, Moller HJ. Amisulpiride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88: 107-117.
13. Pailliere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulipride. Am J Psychiatry 1995; 152: 130-133.
14. Kay SR, Fizbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-267.
15. Kay SR. Positive and Negative Syndromes in Schizophrenia: Assessment and Research. New York: Brunner/Mazel, 1991.
16. Peuskens J, Moller HJ, Puech A. Amisulpiride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002; 12: 305-310.
17. Kay SR, Lindenmeyer J. Outcome predictors in acute schizophrenia: Prospective significance of background and clinical dimensions. J Nerv Ment Dis 1987; 175: 152-160.
18. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8: 59-70.
19. Kelley ME, van Kammen DP, Allen DN. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 1999; 156: 406-411.